CurrentRheuma
Get Weekly

CurrentRheuma coverage · page 5 of 15

Annals of the Rheumatic Diseases

Briefs 161–200 of 596 CurrentRheuma has covered from this journal, newest publication first

Latest from Annals of the Rheumatic Diseases

All coverage, newest first

  1. Ann Rheum Dis

    Development and validation of a EULAR disease activity score in antiphospholipid syndrome

    Diagnostic or prognostic studyLupus & APS

  2. Ann Rheum Dis

    A de novo dominant-negative PSMB8 mutation causes severe CANDLE/PRAAS due to arrested proteasome biogenesis

    Mechanistic studyAutoinflammatory & rare

  3. Ann Rheum Dis

    Evaluation of pregnancy outcomes in patients with spondyloarthritis compared to the general population: results from a French national prospective and matched study

    Cohort studySpondyloarthritis & PsA

  4. Ann Rheum Dis

    Final validation of the hierarchical framework for outcomes in axial spondyloarthritis: longitudinal determinants of health-related quality of life

    Cohort studySpondyloarthritis & PsA

  5. Ann Rheum Dis

    25-Hydroxyvitamin D levels are associated with mortality and cardiovascular events in systemic lupus erythematosus

    Cohort studyLupus & APS

  6. Ann Rheum Dis

    Effects of clofutriben, a selective 11β-hydroxysteroid dehydrogenase type 1 inhibitor, on the efficacy and toxicity of prednisolone in patients with polymyalgia rheumatica: a single-blind controlled trial with sequential cohorts

    Research articleVasculitis & PMR

  7. Ann Rheum Dis

    CD3+ immune cell endotypes are associated with PsA disease phenotype and response to advanced therapy: an integrated mass cytometry and proteomics cohort study

    Cohort studySpondyloarthritis & PsA

  8. Ann Rheum Dis

    Inadequate response to anti-TNFα therapy is associated with a gain-of-function TNFR2-R polymorphic variant in patients with psoriatic arthritis

    Mechanistic studySpondyloarthritis & PsA

  9. Ann Rheum Dis

    Low-dose belimumab reduced risk of flares in patients with systemic lupus erythematosus: a multicentre, randomised, double-blind, placebo-controlled trial

    Randomized controlled trialLupus & APS

  10. Ann Rheum Dis

    Tirzepatide and change in uric acid and its association with weight reduction: post hoc analyses of the SURMOUNT-1 randomised placebo-controlled trial

    Secondary analysisGout & crystals

  11. Ann Rheum Dis

    EULAR 2025 classification criteria for haemochromatosis arthropathy

    Guideline or statementOsteoarthritis

  12. Ann Rheum Dis

    Difficult-to-treat rheumatoid arthritis: systematic review and meta-analysis on global prevalence

    Meta-analysisRA

  13. Ann Rheum Dis

    Understanding the drivers of BASDAI and back pain scores in psoriatic arthritis

    Cohort studySpondyloarthritis & PsA

  14. Ann Rheum Dis

    Association between socioeconomic status and patient delay in rheumatoid arthritis: linking self-reported and national registry data

    Cohort studyRA

  15. Ann Rheum Dis

    EULAR points to consider and consensus definitions for difficult-to-manage and treatment-refractory psoriatic arthritis

    Guideline or statementSpondyloarthritis & PsA

  16. Ann Rheum Dis

    GZMK+CD8+ T cells target a specific acinar cell type in Sjögren's disease

    Mechanistic studySjögren's & overlap

  17. Ann Rheum Dis

    Autoreactive T cells identified in patients with anti-Jo1+ antisynthetase syndrome recognise a new epitope on histidyl t-RNA synthetase

    Mechanistic studyMyositis

  18. Ann Rheum Dis

    Insights from a novel monogenic autoinflammatory disease: overview of a multicentric European cohort of 38 patients with COPA syndrome

    Cohort studyAutoinflammatory & rare

  19. Ann Rheum Dis

    METTL1-mediated internal m7G methylation of cathepsin B mRNA promotes synovial aggression in rheumatoid arthritis

    Mechanistic studyRA

  20. Ann Rheum Dis

    Spatial profiling of giant cell arteritis tissues reveals immune heterogeneity and potential predictors of glucocorticoid response

    Mechanistic studyVasculitis & PMR

  21. Ann Rheum Dis

    Deconstruction of tophi and synovium defines SPP1+ macrophages involved in extracellular matrix remodelling in gout

    Mechanistic studyGout & crystals

  22. Ann Rheum Dis

    EULAR recommendations for the management of systemic lupus erythematosus with kidney involvement: 2025 update

    Guideline or statementLupus & APS

  23. Ann Rheum Dis

    Entheseal tissue signature in response to IL-17A inhibition in psoriatic arthritis: results from the EBIO entheseal biopsy study

    Mechanistic studySpondyloarthritis & PsA

  24. Ann Rheum Dis

    Enhanced proteasome activity in perifascicular myofibres is a hallmark of dermatomyositis and its inhibition is efficient in preclinical models

    Mechanistic studyMyositis

  25. Ann Rheum Dis

    Healthy human enthesis stromal cells mediate immunoregulation via the CD39/CD73 adenosine ectonucleotidase pathway

    Mechanistic studySpondyloarthritis & PsA

  26. Ann Rheum Dis

    Innate immune cell subsets are enriched in synovial fluid of ACPA-negative rheumatoid arthritis and characterized by distinct type I IFN gene signatures

    Mechanistic studyRA

  27. Ann Rheum Dis

    Short-chain fatty acids and their gut microbial pathways distinguish rheumatoid arthritis in discordant monozygotic twins

    Case-control studyRA

  28. Ann Rheum Dis

    The likelihood of joint inflammation recurrence in previously affected joints during psoriatic arthritis disease course

    Cohort studySpondyloarthritis & PsA

  29. Ann Rheum Dis

    Augmentation of immunothrombosis as a key mechanism underlying JAK inhibition associated hypercoagulability in rheumatoid arthritis

    Mechanistic studyRA

  30. Ann Rheum Dis

    Development and validation of a Disease Activity index for PSoriatic Arthritis based on 44 joints (DAPSA44)

    Diagnostic or prognostic studySpondyloarthritis & PsA

  31. Ann Rheum Dis

    Use of statins and its association with major adverse cardiovascular events with tofacitinib vs TNF inhibitors in patients with rheumatoid arthritis with and without atherosclerotic cardiovascular disease

    Secondary analysisRA

  32. Ann Rheum Dis

    Integrative spatial multiomics analysis reveals regulatory mechanisms of VCAM1+ proximal tubule cells in lupus nephritis

    Mechanistic studyLupus & APS

  33. Ann Rheum Dis

    Inhibition of structural damage progression with the selective interleukin-23 inhibitor guselkumab in participants with active PsA: results through week 24 of the phase 3b, randomised, double-blind, placebo-controlled APEX study

    Randomized controlled trialSpondyloarthritis & PsA

  34. Ann Rheum Dis

    The impact of population ageing on musculoskeletal disorders in 204 countries and territories, 1990-2021: global burden and healthcare costs

    Research articleAcross diseases

  35. Ann Rheum Dis

    Myositis-specific autoantibodies recognising Mi2 also target the AIRE protein at a shared PHD zinc finger

    Mechanistic studyMyositis

  36. Ann Rheum Dis

    IL-2 signalling sustains pathogenic age-associated B cell homeostasis in lupus

    Mechanistic studyLupus & APS

  37. Ann Rheum Dis

    Association of health literacy with disease outcomes in inflammatory arthritis: a systematic review

    Meta-analysisRA

  38. Ann Rheum Dis

    Multiomics analysis uncovers subtype-specific mechanisms and biomarkers in idiopathic inflammatory myopathies

    Mechanistic studyMyositis

  39. Ann Rheum Dis

    Discovery of tissue-specific proteomic signatures in juvenile dermatomyositis highlights pathways reflecting persistent disease activity, clinical heterogeneity, and myositis-specific autoantibody subtype

    Mechanistic studyPediatric

  40. Ann Rheum Dis

    ASAS recommendations on reporting axial spondyloarthritis clinical trials

    Guideline or statementSpondyloarthritis & PsA

All 596 Briefs in ExploreShowing Briefs 161–200 of 596, newest first